Drugs.com Clinical Trial ResultsOriginal article
GSK Presents Positive Registrational Data to Potentially Expand Jideytro (zidesamtinib) to First-Line ROS1-Positive Non-Small Cell Lung Cancer
Data ReadoutpositiveJideytroPositive
AI Analysis
Summary
GSK announced positive registrational data from the ARROS-1 phase I/II trial of Jideytro (zidesamtinib) in ROS1-positive non-small cell lung cancer, potentially supporting first-line expansion of the therapy.
Clinical Trial Data
Phase
I/II
Primary Endpoint
Met
Outcome Details
Positive registrational data from phase I/II ARROS-1 trial in ROS1-positive NSCLC
Importance:7/10
Sentiment:
0.85
oncologylung cancerROS1-positiveregistrational trialfirst-lineprecision medicine
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 13, 2026 10:09 PM